Role of redox iron towards an increase in mortality among patients: a systemic review and meta-analysis
- PMID: 31309086
- PMCID: PMC6614104
- DOI: 10.5045/br.2019.54.2.87
Role of redox iron towards an increase in mortality among patients: a systemic review and meta-analysis
Abstract
An increase in biochemical concentrations of non-transferrin bound iron (NTBI) within the patients with an increase in serum iron concentration was evaluated with the following objectives: (a) Iron overloading diseases/conditions with free radicle form of 'iron containing' reactive oxygen species (ROS) and its imbalance mediated mortality, and (b) Intervention with iron containing drugs in context to increased redox iron concentration and treatment induced mortality. Literature search was done within Pubmed and cochrane review articles. The Redox iron levels are increased during dys-erythropoiesis and among transfusion recipient population and are responsive to iron-chelation therapy. Near expiry 'stored blood units' show a significant rise in the ROS level. Iron mediated ROS damage may be estimated by the serum antioxidant level, and show reduction in toxicity with high antioxidant, low pro-oxidant levels. Iron drug therapy causes a significant increase in NTBI and labile iron levels. Hospitalized patients on iron therapy however show a lower mortality rate. Serum ferritin is a mortality indicator among the high-dose iron therapy and transfusion dependent population. The cumulative difference of pre-chelation to post chelation ROS iron level was 0.97 (0.62; 1.32; N=261) among the transfusion dependent subjects and 2.89 (1.81-3.98; N=130) in the post iron therapy 'iron ROS' group. In conclusion, iron mediated mortality may not be mediated by redox iron among multi-transfused and iron overloaded patients.
Keywords: Chelation antioxidants; Hepcidin; Non transferrin bound iron; Pro-oxidant effect; Serum ferritin; Transferrin saturation.
Conflict of interest statement
Authors' Disclosures of Potential Conflicts of Interest: No potential conflicts of interest relevant to this article were reported.
Figures





Similar articles
-
Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.Br J Haematol. 2017 Jan;176(2):288-299. doi: 10.1111/bjh.14373. Epub 2016 Dec 5. Br J Haematol. 2017. PMID: 27917462 Free PMC article. Clinical Trial.
-
Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.Am J Hematol. 2012 Jan;87(1):55-61. doi: 10.1002/ajh.22203. Epub 2011 Nov 28. Am J Hematol. 2012. PMID: 22125177
-
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.Haematologica. 2017 Oct;102(10):1640-1649. doi: 10.3324/haematol.2017.170605. Epub 2017 Jun 22. Haematologica. 2017. PMID: 28642302 Free PMC article.
-
Iron and oxidative stress in cardiomyopathy in thalassemia.Free Radic Biol Med. 2015 Nov;88(Pt A):3-9. doi: 10.1016/j.freeradbiomed.2015.07.019. Epub 2015 Jul 26. Free Radic Biol Med. 2015. PMID: 26216855 Review.
-
Non-transferrin bound iron: a key role in iron overload and iron toxicity.Biochim Biophys Acta. 2012 Mar;1820(3):403-10. doi: 10.1016/j.bbagen.2011.07.014. Epub 2011 Aug 9. Biochim Biophys Acta. 2012. PMID: 21855608 Review.
References
-
- Brunskill SJ, Wilkinson KL, Doree C, Trivella M, Stanworth S. Transfusion of fresher versus older red blood cells for all conditions. Cochrane Database Syst Rev. 2015:CD010801. - PubMed
Publication types
LinkOut - more resources
Full Text Sources